HYDROXYSTILBAMIDINE ISETHIONATE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Hydroxystilbamidine Isethionate is a small-molecule injectable drug approved in 1953 with an unknown mechanism of action and indication profile. The drug's therapeutic area and clinical utility remain poorly documented in modern literature, reflecting its age and legacy status.
LOE Approaching
With LOE approaching and minimal commercial data, this product likely operates with a small, maintenance-focused team managing legacy patient populations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers minimal career growth or development opportunities due to its legacy status, approaching LOE, and zero linked job openings. Roles available are maintenance-focused with limited innovation or advancement trajectory.
Product Manager (Legacy)Regional Sales Manager
Worked on HYDROXYSTILBAMIDINE ISETHIONATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.